Insights

The Shift Toward US Pharmaceutical Manufacturing: Considerations in Attaining the Right Global Mix

icons/content-types/white paper white paper

General

The COVID-19 pandemic has brought the global interdependency of pharmaceutical supply chains into sharp focus, exposing weak links and re-igniting discussions around the value of reshoring production. The U.S. Food and Drug Administration (FDA) reports 72% of facilities manufacturing APIs for American drugs are overseas, with 13% in China. Download our white paper where we discuss effective strategies to secure and de-risk pharmaceutical supply chains and reveal how Curia assures the continual production of urgently needed drugs.

View resource 0088AE5F-29AA-4BF7-826D-52FA93D463D0

Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

Contact Us
More from Curia

icons/content-types/white paper white paper

Revolutionizing Small Molecule API Production:
Unveiling the Impact of Fermentation as a Sustainable Solution

While large molecules continue to advance in drug development pipelines, small molecule Active Pharmaceutical Ingredients (APIs) still retain their historical dominance among new drug applications (NDAs). However, the last few years have seen the lin...

icons/content-types/white paper white paper

FDA's Quality Management Maturity Program:
Why should CDMOs adhere to the new CDER's Rating System?

Ensuring the safety and efficacy of pharmaceutical products is paramount in the healthcare industry, making the FDA's Quality Management Maturity (QMM) program and CDER's proposed rating system crucial for Contract Development and Manufacturing Organ...